NCT06966284招募中不适用
A Retrospective, Observational, Post-Marketing Study to Assess the Efficacy and Safety of Intravenous Infusions Polymyxin B and Colistin Methanesulfonate in Patients With Carbapenem-Resistant Gram-Negative Bacterial Infection
TTY Biopharm1 个研究点 分布在 1 个国家目标入组 480 人开始时间: 2025年11月26日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 480
- 试验地点
- 1
- 主要终点
- Clinical response rate of polymyxin B and CMS treatment groups at TOC
研究概览
简要总结
This is a retrospective, observational, post-marketing study to evaluate the clinical response, microbiological response, mortality, and safety of intravenous polymyxin B and colistin methanesulfonate in patients with carbapenem-resistant gram-negative bacterial infection. Subgroup analysis by sites of infection, infectious pathogens, and baseline renal function will also be performed.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient ≥ 18 years of age.
- •Patient diagnosed with bacterial pneumonia and/or bacteremia, or other physician judged serious infection (except urinary tract infection, UTI) caused by Carbapenem-Resistant Gram-Negative Bacteria (CR-GNB).
- •CR-GNB: Resistant to at least one of the carbapenem antibiotics or produce a carbapenemase (an enzyme that can make them resistant to carbapenem antibiotics).
- •Diagnosis Criteria of HABP/VABP:
- •Met the clinical diagnosis criteria for HABP/VABP. HABP: Acute bacterial pneumonia in a subject hospitalized for more than 48 hours or developing within 7 days after discharge from a hospital. Subject could have experienced acute respiratory failure and required mechanical ventilation for HABP.
- •VABP: Acute bacterial pneumonia in a subject receiving mechanical ventilation via an endotracheal (or nasotracheal) tube for a minimum of 48 hours.
- •≥ 1 of the following clinical features: new onset or worsening of pulmonary symptoms or signs, hypoxemia, need for acute changes in the ventilator support system to enhance oxygenation, new onset of or increase in suctioned respiratory secretions.
- •≥ 1 of the following signs: documented fever, hypothermia, WBC ≥ 10,000 cells/mm3, WBC ≤ 4500 cells/mm3, >15% immature neutrophils(bands)
- •CXR or lung CT: presence of new or progressive infiltrates suggestive of bacterial pneumonia.
- •Diagnosis Criteria of BSI/Bacteremia: the BSI/sepsis category included bacteremia or sepsis caused by infections other than HABP/VABP, or UTI:
- •Documented BSI caused by a carbapenem-resistant Gram-negative pathogen; or
- •Systemic response to infection, meeting the clinical criteria of SIRS and an identified infection source (eg, severe skin infection, intra-abdominal infection) caused by a carbapenem-resistant Gram-negative pathogen.
- •Patient received intravenous polymyxin B or CMS treatment for ≥72 h.
- •Administration of polymyxin B or CMS within 7 days from the infection onset day.
- •Infection onset day: The date of specimen collection for index pathogen.
排除标准
- •Patient with bacteremia caused by urinary tract infection.
- •CR-GNB known to be resistant to polymyxin B or CMS.
- •Patient has infectious disease (s) caused by the following gram-negative bacteria which are known to have no response to polymyxin B and/or colistin treatment: Proteus spp., Providencia spp., Morganella spp., Serratia marcescens, Burkholderia spp., and Neisseria spp.
- •Intravenous administration of polymyxin B or colistin more than 28 days.
- •Both the treatment efficacy and safety could not be evaluated.
研究组 & 干预措施
Experiment: Polymyxin B
Comparator: colistin methanesulfonate
结局指标
主要结局
Clinical response rate of polymyxin B and CMS treatment groups at TOC
时间窗: TOC: End of Treatment + 7 days
Microbiological response rate of polymyxin B and CMS treatment groups at TOC
时间窗: TOC: End of Treatment + 7 days
All-cause mortality of of polymyxin B and CMS treatment groups at Day 28
时间窗: Day 28 from start of treatment
Clinical response rate of polymyxin B group by sites of infection and infectious pathogens at TOC
时间窗: End of Treatment + 7 days
Microbiological response rate of polymyxin B group by sites of infection and infectious pathogens at TOC
时间窗: End of Treatment + 7 days
Infection-related mortality of two treatment groups at Day 28
时间窗: Day 28 from start of treatment
次要结局
- Clinical response rate (Day 7, Day 14, Day 28, and EOT) of two treatment groups(Day 7, Day 14, Day 28, and EOT)
- Clinical response rate (Day 7, Day 14, Day 28 and EOT) of polymyxin B group by sites of infection and infectious pathogens(Day 7, Day 14, Day 28, and EOT)
- Clinical response rate (Day 7, Day 14, Day 28, EOT, and TOC) of polymyxin B group by baseline renal function(Day 7, Day 14, Day 28, EOT, and TOC)
- Microbiological response rate (Day 7, Day 14, and EOT) of two treatment groups(Day 7, Day 14, and EOT)
- Microbiological response rate (Day 7, Day 14, and EOT) of polymyxin B group by sites of infection and infectious pathogens(Day 7, Day 14, and EOT)
- Microbiological response rate (Day 7, Day 14, EOT, and TOC) of polymyxin B group by baseline renal function(Day 7, Day 14, EOT, and TOC)
- All-cause mortality (Day 14) of two treatment groups(Day 14 from start of treatment)
- All-cause mortality (Day 14, Day 28) of polymyxin B group by sites of infection, infectious pathogens, and baseline renal function(Day 14, Day 28 from start of treatment)
- Infection-related mortality (Day 14) of two treatment groups(Day 14 from start of treatment)
- Infection-related mortality (Day 14, Day 28) of polymyxin B group by sites of infection, infectious pathogens, and baseline renal function(Day 14, Day 28 from start of treatment)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
PMCF to Assess Real-life Usage Effectiveness, Safety and Patient Satisfaction of a Range of Hypertonic Seawater-based Decongestant Nasal SpraysURTIAllergic RhinitisNCT06104332Laboratoire de la Mer534
Unknown
不适用
Post Marketing Clinical Follow up Study to Evaluate the Performance and Safety of ORTHIX PLUSDegenerative Joint Disease of KneeOsteoarthritis, KneeNCT05348525Yooyoung Pharmaceutical Co., Ltd.54
Unknown
不适用
Post Marketing Clinical Follow up Study to Evaluate the Performance and Safety of HYALEXODegenerative Joint DiseaseOsteoarthritisNCT05229458Yooyoung Pharmaceutical Co., Ltd.54
已完成
不适用
LifeVest Safety and Efficacy in Real Life Settings in FranceLeft Ventricular DysfunctionCardiac EventCardiac ArrythmiasSudden Cardiac DeathNCT03319160Zoll Medical Corporation1,164
招募中
不适用
Clinical Investigation on the Outcome of Episealer Talus Post-operation for Treatment of Focal Osteochondral DefectsOsteochondral DefectNCT06225674Episurf Medical Inc.25